Self-affirmed GRAS or FDA-notified: which do my customers accept, and is self-affirmed going away?

The short answer. Filing a GRAS notice is optional today. The regulation that carries the program is headed “Opportunity to submit a GRAS notice” and says any person may notify FDA of a view that a substance is not subject to premarket approval, based on that person’s own conclusion (eCFR, 21 CFR part 170, opportunity to submit a GRAS notice). What your customer requires is a separate question with a different answer, and it is the one that actually stops a shipment. On 11 August 2026 FDA published a proposed rule that would make the notice mandatory. It is a proposal. It is not law yet.

Before you read any further, check where the ingredient is going. If it is a dietary ingredient in, or intended for use in, a dietary supplement, this entire pathway is closed to you, and the food additive requirements below are not the ones you are under. The statute excludes such an ingredient from the definition of “food additive” outright (21 U.S.C. 321(s)(6)), and GRAS is a carve-out inside that definition. FDA says so in the proposed rule in its own words: uses excluded under those paragraphs “cannot be the subject of a GRAS notice,” and “are not eligible for classification as GRAS under the GRAS provision included in the definition of ‘food additive’” (FDA, proposed rule, Substances Generally Recognized as Safe, 91 FR 51834). A supplier who hands you a “self-affirmed GRAS” letter for a supplement ingredient has handed you a document about the wrong statute. What binds there is the new dietary ingredient provision, and it is covered further down.

What this page does not reach. It covers United States federal law on the two pathways in the question. It does not cover food additive petitions, color additives, food contact substances, animal food, or the European novel food route, each of which is its own decision. It does not tell you whether your ingredient is GRAS; that is a scientific conclusion about the state of expert opinion, not something a page can settle.

What “self-affirmed” actually means

“Self-affirmed” is the trade’s word. Read the definition it comes from. A substance is a food additive if its intended use results, or may reasonably be expected to result, directly or indirectly, in it becoming a component of, or otherwise affecting the characteristics of, any food, and if that substance “is not generally recognized, among experts qualified by scientific training and experience to evaluate its safety, as having been adequately shown through scientific procedures (or, in the case of a substance used in food prior to January 1, 1958, through either scientific procedures or experience based on common use in food) to be safe under the conditions of its intended use” (21 U.S.C. 321(s)).

GRAS is the second half of that sentence. General recognition is what keeps a substance outside the definition, and read what that recognition is made of: recognition among experts qualified by scientific training and experience, shown through scientific procedures, or for a substance used in food before 1 January 1958 through common use in food, and all of it measured against the conditions of your intended use. Either that recognition holds for your use or it does not, and the answer is the same on the day you launch whether or not anyone outside your company has looked.

That is why the shortcut is tempting and why it is fragile in the same breath. FDA’s own name for it in the proposed rule is plainer than the industry’s: an independent conclusion of GRAS status, meaning a conclusion reached without submitting a notice (FDA, proposed rule, 91 FR 51834). Independent of FDA. Not independent of you.

If the conclusion is wrong, the consequence is not a rejected filing. The substance was inside the food additive definition from the start, because that definition turns on whether general recognition holds and not on when anyone reads it. A food additive is deemed unsafe unless one of the conditions in that subsection is met, and for an ordinary added ingredient that condition is a regulation in effect prescribing the conditions under which the additive may safely be used, with the additive and its use in conformity with that regulation (21 U.S.C. 348(a); 348(a)(2)). The statute ties that deeming to the food adulteration clause of section 342(a) in its own words (21 U.S.C. 348(a)), and introducing adulterated food into interstate commerce is a prohibited act (21 U.S.C. 331(a)).

What an FDA letter is, and what it is not

File a notice and FDA responds by letter, within 180 days of filing, extendable by 90 days (eCFR, 21 CFR part 170, what FDA will do with a GRAS notice). The good outcome is the letter the industry calls a no-questions letter. In the proposed rule FDA writes out what that letter is, and the second half of the sentence is the half that matters: a no-questions letter “is neither an affirmation by FDA that the notified substance is GRAS for its intended conditions of use … nor a published finding … declaring the use of such substance exempt from the term ‘food additive’ because of its being GRAS” (FDA, proposed rule, 91 FR 51834).

So notifying does not transfer the conclusion to FDA. It remains yours. What the notice buys you is that a reviewer outside your company read the dossier and did not object, and that the dossier and the letter sit in a public inventory anyone can look up. That is a real difference to a customer, and it is a smaller difference in law than the phrase “FDA-notified” suggests.

The reverse also holds, and it is the assumption that catches people. Silence is not clearance. FDA proposes to state it in the regulation: “The fact that FDA has not made such a determination does not mean that a substance is GRAS under the conditions of its intended use” (FDA, proposed rule, 91 FR 51834). Years on the market without a letter from anyone is not evidence of anything except that nobody has looked yet.

Which pathway reaches your ingredient

These are not alternatives you pick between. Where the ingredient goes decides which pathway is even available to you, and an ingredient sold into both food and supplements sits in two rows at once.

The fifth row is where most of the argument happens, and it is worth reading twice. It asks whether the ingredient has been present in the food supply as an article used for food. It does not ask whether the ingredient is safe, whether a panel said so, or whether anyone holds a GRAS conclusion on it. A GRAS dossier is not evidence for that row. If your file rests on that exemption, the evidence it needs is evidence of use as food, in a form that was not chemically altered.

Where a product is sold as a drink but wears a Supplement Facts panel, the row it belongs in changes and so does the answer. A constructed case on that exact boundary walks it through; and if you are not certain which category your product is in before you get to the ingredient, that question is answered first in our piece on how the four categories are decided.

What your customers are actually asking for

Here is the part the statute cannot answer. Your customer is not enforcing the FD&C Act. They are protecting themselves, usually through a certification scheme or a supplier specification, and those documents say what they want in writing.

Take the dietary supplement certification standard. It requires the certifying body to review every dietary ingredient in a formulation and, where no established upper safe level or typical use level exists for it, to determine whether the ingredient is allowed for use in food per FDA or whether a threshold is available from an authoritative body. Only where no such threshold is available does the standard reach the next question, which is whether the company seeking certification can provide a self-affirmed GRAS conclusion, a history-of-safe-use assessment, or documentation of compositional equivalence to an ingredient with an established level. So a self-affirmed conclusion is accepted by that scheme. Then read the note that qualifies it: “A full self-affirmed GRAS dossier reviewed by an expert panel may be used to demonstrate safety at the MUL; standalone GRAS statements without supporting documentation are not considered sufficient”, the MUL being the standard’s maximum use level, the maximum daily intake based on the product label (NSF/ANSI 173, ingredient acceptability).

That is the whole commercial answer in one sentence. The dossier is accepted. The one-page statement of it is not. A great deal of what circulates in the trade as “self-affirmed GRAS” is the statement without the dossier under it, and the moment a certifier or a large customer asks for the file behind it, the difference stops being a formality.

The same standard is candid about what it is not doing for you: “Demonstration of regulatory compliance is not in scope of the standard and is the responsibility of product manufacturers” (NSF/ANSI 173, ingredient acceptability). Certification is not a legal opinion, and it does not move your obligation anywhere.

On the specification side the ask is more mundane and more frequently missed. An audited dietary supplement operation holds specifications which shall, where applicable, carry regulatory and compliance information, and that information shall include the ingredient’s “Regulatory status and corresponding CFR reference.” The standard says that status “shall indicate but not be limited to” pre-DSHEA status, new dietary ingredient status, “Generally Recognized as Safe (GRAS) status, including conditions of intended use,” and food additive status (NSF Dietary Supplements GMP Requirements, supplier specification content). Note the four words at the end of the GRAS line. Not “GRAS: yes.” The conditions of intended use, which means the use your customer is putting it to has to be inside the use your conclusion covered.

The mistake this gets caught on

Strip the acronyms and the failure is an ordinary one: a check arranged and paid for by the party being checked. A panel your company convened, reading a dossier your company wrote, about an ingredient your company sells. That can be excellent work and often is. It is still not the same thing as an outside body finding what it exists to find, and every buyer with an audit function knows it. The certification standard’s own qualifier is the industry conceding the point in writing: the dossier and the panel are accepted, the bare statement is not.

The regulator’s record shows what the failure costs. FDA maintains a public inventory of post-market determinations that the use of a substance is not GRAS, many of them carrying the scientific memorandum behind it. FDA says its scientists may document such a determination in a memo, and that the inventory is not a complete list of the substances whose intended use in food is not GRAS (FDA, post-market determinations that the use of a substance is not GRAS). These are read after the product is on shelves, not before.

Tara flour is the case FDA itself puts in the preamble. A firm used it in a human food, then recalled the product after roughly 400 adverse event reports describing gastrointestinal distress, hepatotoxicity and hospitalisation. FDA writes: “We requested, but the firm did not share with FDA any records or other indication that demonstrated that they had reached a GRAS conclusion regarding the use of tara flour in human food.” FDA then determined there were not enough data to consider it GRAS, and no regulation authorized it (FDA, proposed rule, 91 FR 51834). The memorandum is dated 10 April 2024, after the recall.

The second is Delta-8 THC. FDA warned firms that the use of the substance in conventional foods did not meet the criteria for GRAS status in its regulations, and that the products therefore contained an unsafe food additive rendering them adulterated (FDA, proposed rule, 91 FR 51834). In both, the products were made, sold and bought first. The reading came afterwards.

What good looks like is not complicated, and it is not a certificate. It is a file another qualified person could pick up and reach the same conclusion from: the identity of the material you actually ship rather than an idealised version of it, the exposure across every product it goes into rather than one serving, the published evidence at that exposure, and a written determination signed by someone qualified to make it.

Is self-affirmed going away?

It is being proposed away. Here are the dates, and what is and is not settled.

On 10 March 2025 the Secretary of Health and Human Services directed FDA to explore rulemaking to eliminate the pathway for firms to introduce purported GRAS uses into the market without notifying FDA of the basis for their conclusions. FDA records the direction in the preamble to its own rule (FDA, proposed rule, 91 FR 51834).

On 11 August 2026 FDA published the proposed rule that answers that direction, under docket FDA-2025-N-3262. The operative sentence would replace the word “may” with “must”: “Any person introducing a substance into interstate commerce under the GRAS provision … must notify FDA of the basis for their conclusion that the substance is GRAS under the conditions of its intended use,” subject to a list of exceptions (FDA, proposed rule, 91 FR 51834). Comments close on 9 December 2026.

Four things about it are worth holding on to.

• It is a proposal. Nothing in it binds anyone today, and a proposed rule can be changed or dropped between proposal and final.
• The runway is long and it is stated. FDA intends any final rule to take effect 60 days after the final rule publishes, and proposes that the notification sections carry a compliance date 18 months after that effective date (FDA, proposed rule, 91 FR 51834).
• There is a lighter route for what is already on the market, and it closes. For a substance introduced into commerce before the effective date on an independent GRAS conclusion, FDA proposes a time-limited streamlined submission, open for one year from the effective date, which would except that use from having to file a full notice once it appears on a public list, unless FDA determines that a notice or a food additive petition must be submitted for that use. FDA is explicit that appearing on the list “would not represent a determination by FDA that the use of the substance is GRAS or does not require a food additive petition” (FDA, proposed rule, 91 FR 51834).
• It does not reach dietary supplements. The proposal is written inside the food additive definition, and a supplement ingredient is outside it (21 U.S.C. 321(s)(6)).

So the honest answer to the question as asked: self-affirmation is not going away this year, and if your ingredient goes into supplements it was never the rule you were under. If your ingredient goes into food, the direction of travel is one way, the timetable is now visible, and the cheapest moment to find out whether your dossier holds is before a deadline makes it someone else’s reading.

Three things to check on your own file

1. Check where it actually goes, product by product. Not the category on the sales sheet. If the same ingredient goes into a beverage and a capsule, two different provisions apply to it and only one of them has a GRAS route.
2. Check whether the dossier exists, or only the statement. Ask for the pages: the identity of the shipped material, the exposure estimate across the whole line, the published evidence, and the signed determination. If what comes back is a one-page letter, that is what your customer’s certifier will find too.
3. Check the conditions of use against your customer’s use. A conclusion is bounded by the use it was written for. A supplier’s file written for a flavor at low addition rates does not carry a hero ingredient at ten times the level, and the specification line your customer keeps asks for the conditions, not the label.